Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Industry continues to join forces to find new treatments for COVID-19.
September 8, 2020
By: Dohyun Cho
Chief Operating Officer, Enzychem Lifesciences
The life sciences’ industry response to the current global COVID-19 pandemic has highlighted the importance of innovation and drug development in the anti-infectives and antiviral space. During this time of need, it has also highlighted our industry’s ability to come together and share resources, across borders, during a time of extreme need. One thing is certain—we need new treatments for COVID-19, whether it be therapeutics or vaccines, and soon. Biotech and pharma companies globally are developing everything from antivirals and vaccine platforms, to DNA synthesis and antibodies, companies have put their best bet forward to try and defend the human population against this threat. According to BIO, based on their COVID-19 Therapeutic Development Tracker, there are currently 707 unique active compounds in development. 270 are clinical compounds in development and the vast majority, 437 are preclinical compounds in development. As of today, hundreds of drugs are currently in various stages in clinical trials, from vaccines, to antivirals, small molecules, antibodies, to CAR-T therapies. The vast majority of therapies in development are in Phase 2 trials. Currently, only two drugs have been approved for emergency use by the U.S. FDA, Gilead Science’s remdesivir, and convalescent plasma—which has been controversial and widely debated and contested in the media. However, as well-intentioned and committed as the industry response has been thus far, it is time to begin asking both ourselves, and our policy makers, why such a response was necessary. For example, we currently have the technology to build a vast centralized network of known antivirals for rapid screening against emerging threats. Why is it not in place? The U.S. has the technology to build rapid response systems to prevent pandemics. In South Korea, the Ministry of Food and Drug Safety, has approved 22 clinical trials to develop Covid-19 treatments and vaccines. Five of the 22 trials have been completed with the other 17 in progress. Korean pharmaceutical companies are now conducting 12 trials, with seven studies in Phase 2 and the five others are in Phase 1. Enzychem Lifesciences is one of the seven companies selected by Korean regulators to conduct a Phase 2 study. Researchers now believe some of the most severe complications of the coronavirus may be caused by an overactive immune system. Cytokine storm is an uncontrolled release of proteins that triggers a massive inflammatory response. This “overreaction” of the body’s natural immune defense can destroy vital organs, which is why we decided to focus on developing a therapy that would stop this cascade of symptoms and effects in the body. There is currently no proven treatment for a coronavirus-induced cytokine storm. EC-18 has been shown pre-clinically to control neutrophil infiltration, thereby modulating the inflammatory cytokine and chemokine signaling that has been implicated in severe COVID-19 cases. Dr. Cameron Wolfe, an infectious disease expert and head of Duke Medical’s Coronavirus Task Force, will lead our U.S. clinical program in COVID-19. Enzychem is only one of many international biopharmaceutical companies developing a potential therapeutic in the U.S in the fight against COVID-19. According to the CDC Covid Data Tracker, there are currently over 6 million cases of COVID-19 in the U.S., with over 180,000 total deaths. In the last 7 days, there were close to 300,000 confirmed cases alone. Some states have more cases than the entire country of Canada right now. If there was ever a time for the life sciences industry to come together, share resources, knowledge and data, the time is now. Since COVID-19 was first reported, scientists all over the world have worked with remarkable speed to understand the virus and share findings and knowledge. Despite how poorly regarded and misunderstood the pharma industry is by the wider population—58% of Americans hold a negative view of our industry based on the 2019 Gallup survey, and ranked us last, scientists and researchers in our field continue to press on. Our hope is that the wider public will change its views towards the pharma industry, as scientists and researchers work tirelessly around the clock to bring a potential therapy or vaccine to patients in this race against time.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !